Washington DC, April 12th 2013
The Orphan Drug meeting US has completed today the three days agenda. Six hundred delegates have attended the largest commercial gathering for Orphan Drugs, held in Washington D.C. Exhibitors and keynote speakers covered several key topics including:
- Regulatory pathways
- Pricing and reimbursement
- Clinical trial aspects for Orphan Drug
- Patient Registries and treatment follow up
- The role of patient associations in access to therapy and funding research
- Partnering and funding orphan drug commercial deals
Genpharm sponsored the event and showcased the MENA region as an untapped market for Orphan Drug companies. “As the sole representative of MENA, I believe we achieved our objectives.”
We raised awareness amongst the Orphan Drug manufacturers as to the potential of our region to be included in pivotal clinical trials and research.
We find no reason as to why MENA patients suffering from rare diseases, should have to wait longer to get access to effective and breakthrough therapies”, said Karim Smaira, CEO of Genpharm. “Several of the companies we met, showed tremendous interest in the region and admitted that they lacked the necessary information”.